vs
Side-by-side financial comparison of Journey Medical Corp (DERM) and FREQUENCY ELECTRONICS INC (FEIM). Click either name above to swap in a different company.
FREQUENCY ELECTRONICS INC is the larger business by last-quarter revenue ($17.1M vs $16.1M, roughly 1.1× Journey Medical Corp). FREQUENCY ELECTRONICS INC runs the higher net margin — 10.5% vs -7.8%, a 18.3% gap on every dollar of revenue. On growth, Journey Medical Corp posted the faster year-over-year revenue change (27.3% vs 8.3%). Over the past eight quarters, FREQUENCY ELECTRONICS INC's revenue compounded faster (11.8% CAGR vs 11.0%).
Journey Medical Corp is a commercial-stage biopharmaceutical company specializing in dermatology treatments. It develops, manufactures and markets prescription and over-the-counter products addressing acne, atopic dermatitis, fungal skin infections and other dermal conditions, primarily serving healthcare providers and patients across the United States.
Ultra Electronics Holdings is a British defence and security company. It was listed on the London Stock Exchange and was a constituent of the FTSE 250 Index until it was acquired by Cobham, which is itself owned by Advent International.
DERM vs FEIM — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $16.1M | $17.1M |
| Net Profit | $-1.2M | $1.8M |
| Gross Margin | — | 38.2% |
| Operating Margin | -2.8% | 10.0% |
| Net Margin | -7.8% | 10.5% |
| Revenue YoY | 27.3% | 8.3% |
| Net Profit YoY | -182.0% | -32.1% |
| EPS (diluted) | $-0.04 | $0.18 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.1M | $17.1M | ||
| Q3 25 | $17.0M | $13.8M | ||
| Q2 25 | $15.0M | $20.0M | ||
| Q1 25 | $13.1M | $18.9M | ||
| Q4 24 | $12.6M | $15.8M | ||
| Q3 24 | $14.6M | $15.1M | ||
| Q2 24 | $14.9M | $15.6M | ||
| Q1 24 | $13.0M | $13.7M |
| Q4 25 | $-1.2M | $1.8M | ||
| Q3 25 | $-2.3M | $634.0K | ||
| Q2 25 | $-3.8M | $3.2M | ||
| Q1 25 | $-4.1M | $15.4M | ||
| Q4 24 | $1.5M | $2.7M | ||
| Q3 24 | $-2.4M | $2.4M | ||
| Q2 24 | $-3.4M | $2.6M | ||
| Q1 24 | $-10.4M | $130.0K |
| Q4 25 | — | 38.2% | ||
| Q3 25 | — | 36.8% | ||
| Q2 25 | — | 37.5% | ||
| Q1 25 | — | 43.8% | ||
| Q4 24 | 82.3% | 48.2% | ||
| Q3 24 | 63.9% | 44.4% | ||
| Q2 24 | 56.0% | 40.3% | ||
| Q1 24 | 47.7% | 22.6% |
| Q4 25 | -2.8% | 10.0% | ||
| Q3 25 | -9.0% | 2.6% | ||
| Q2 25 | -19.2% | 16.4% | ||
| Q1 25 | -25.3% | 18.3% | ||
| Q4 24 | 17.7% | 16.5% | ||
| Q3 24 | -19.8% | 15.7% | ||
| Q2 24 | -19.7% | 16.0% | ||
| Q1 24 | -77.4% | -3.4% |
| Q4 25 | -7.8% | 10.5% | ||
| Q3 25 | -13.6% | 4.6% | ||
| Q2 25 | -25.3% | 16.0% | ||
| Q1 25 | -31.0% | 81.4% | ||
| Q4 24 | 12.1% | 16.8% | ||
| Q3 24 | -16.3% | 16.1% | ||
| Q2 24 | -22.6% | 16.9% | ||
| Q1 24 | -80.1% | 0.9% |
| Q4 25 | $-0.04 | $0.18 | ||
| Q3 25 | $-0.09 | $0.07 | ||
| Q2 25 | $-0.16 | $0.33 | ||
| Q1 25 | $-0.18 | $1.60 | ||
| Q4 24 | $0.10 | $0.28 | ||
| Q3 24 | $-0.12 | $0.25 | ||
| Q2 24 | $-0.17 | $0.28 | ||
| Q1 24 | $-0.53 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $24.1M | $3.0M |
| Total DebtLower is stronger | $25.3M | — |
| Stockholders' EquityBook value | $31.9M | $58.5M |
| Total Assets | $94.6M | $92.3M |
| Debt / EquityLower = less leverage | 0.79× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $24.1M | $3.0M | ||
| Q3 25 | $24.9M | $4.5M | ||
| Q2 25 | $20.3M | $4.7M | ||
| Q1 25 | $21.1M | $5.5M | ||
| Q4 24 | $20.3M | $9.7M | ||
| Q3 24 | $22.5M | $16.2M | ||
| Q2 24 | $23.9M | $18.3M | ||
| Q1 24 | $24.1M | $11.7M |
| Q4 25 | $25.3M | — | ||
| Q3 25 | $25.2M | — | ||
| Q2 25 | $25.1M | — | ||
| Q1 25 | $25.0M | — | ||
| Q4 24 | $24.9M | — | ||
| Q3 24 | $19.8M | — | ||
| Q2 24 | $19.7M | — | ||
| Q1 24 | $14.7M | — |
| Q4 25 | $31.9M | $58.5M | ||
| Q3 25 | $25.9M | $56.3M | ||
| Q2 25 | $19.2M | $55.6M | ||
| Q1 25 | $21.5M | $51.8M | ||
| Q4 24 | $20.1M | $36.2M | ||
| Q3 24 | $10.9M | $33.2M | ||
| Q2 24 | $11.3M | $39.8M | ||
| Q1 24 | $13.0M | $36.7M |
| Q4 25 | $94.6M | $92.3M | ||
| Q3 25 | $85.2M | $93.2M | ||
| Q2 25 | $81.2M | $93.7M | ||
| Q1 25 | $85.0M | $86.4M | ||
| Q4 24 | $80.2M | $77.8M | ||
| Q3 24 | $64.0M | $84.3M | ||
| Q2 24 | $65.2M | $83.3M | ||
| Q1 24 | $66.6M | $77.7M |
| Q4 25 | 0.79× | — | ||
| Q3 25 | 0.97× | — | ||
| Q2 25 | 1.30× | — | ||
| Q1 25 | 1.16× | — | ||
| Q4 24 | 1.24× | — | ||
| Q3 24 | 1.81× | — | ||
| Q2 24 | 1.75× | — | ||
| Q1 24 | 1.13× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.3M | $-523.0K |
| Free Cash FlowOCF − Capex | — | $-1.1M |
| FCF MarginFCF / Revenue | — | -6.6% |
| Capex IntensityCapex / Revenue | — | 3.6% |
| Cash ConversionOCF / Net Profit | — | -0.29× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-5.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.3M | $-523.0K | ||
| Q3 25 | $-2.4M | $1.2M | ||
| Q2 25 | $-942.0K | $-155.0K | ||
| Q1 25 | $-2.8M | $-3.6M | ||
| Q4 24 | $2.2M | $3.8M | ||
| Q3 24 | $-1.2M | $-1.5M | ||
| Q2 24 | $-5.2M | $7.5M | ||
| Q1 24 | $-5.0M | $4.2M |
| Q4 25 | — | $-1.1M | ||
| Q3 25 | — | $385.0K | ||
| Q2 25 | — | $-786.0K | ||
| Q1 25 | — | $-4.0M | ||
| Q4 24 | — | $3.3M | ||
| Q3 24 | — | $-1.8M | ||
| Q2 24 | — | $6.7M | ||
| Q1 24 | — | $3.9M |
| Q4 25 | — | -6.6% | ||
| Q3 25 | — | 2.8% | ||
| Q2 25 | — | -3.9% | ||
| Q1 25 | — | -20.9% | ||
| Q4 24 | — | 20.8% | ||
| Q3 24 | — | -11.8% | ||
| Q2 24 | — | 42.8% | ||
| Q1 24 | — | 28.4% |
| Q4 25 | — | 3.6% | ||
| Q3 25 | — | 5.6% | ||
| Q2 25 | — | 3.2% | ||
| Q1 25 | — | 1.7% | ||
| Q4 24 | — | 3.3% | ||
| Q3 24 | — | 2.2% | ||
| Q2 24 | — | 5.3% | ||
| Q1 24 | — | 2.3% |
| Q4 25 | — | -0.29× | ||
| Q3 25 | — | 1.83× | ||
| Q2 25 | — | -0.05× | ||
| Q1 25 | — | -0.24× | ||
| Q4 24 | 1.46× | 1.44× | ||
| Q3 24 | — | -0.60× | ||
| Q2 24 | — | 2.85× | ||
| Q1 24 | — | 32.36× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
FEIM
| POC Revenue | $14.8M | 86% |
| POT Revenue | $2.3M | 13% |
